PMID- 28524001
OWN - NLM
STAT- MEDLINE
DCOM- 20180718
LR  - 20180718
IS  - 1996-3181 (Electronic)
IS  - 1871-5273 (Linking)
VI  - 16
IP  - 7
DP  - 2017
TI  - Brain-derived Neurotrophic Factor Promotes Growth of Neurons and Neural Stem 
      Cells Possibly by Triggering the Phosphoinositide 3-Kinase/ AKT/Glycogen Synthase 
      Kinase-3beta/beta-catenin Pathway.
PG  - 828-836
LID - 10.2174/1871527316666170518170422 [doi]
AB  - BACKGROUND: Brain-derived neurotrophic factor (BDNF) plays a crucial role in 
      promoting survival and differentiation of neurons and neural stem cells (NSCs), 
      but the downstream regulating mechanisms remain poorly understood. OBJECTIVE: We 
      investigated whether BDNF exerts its effect by triggering the phosphoinositide 
      3-kinase (PI3K), protein kinase B, PKB (AKT), glycogen synthase kinase-3beta 
      (GSK-3beta) and beta-catenin signaling pathway in cultured neurons and NSCs derived 
      from the rat embryonic spinal cord. METHOD: Immunocytochemistry was used to 
      detect neuronal and NSCs characteristics. RT-PCR was used to detect 
      PI3K/AKT/GSK3beta/beta-catenin pathway expression. RESULTS: Neurons and NSCs were 
      successfully separated and cultured from Sprague-Dawley rat embryonic spinal cord 
      and were respectively labeled using immunocytochemistry. Neuron-specific nuclear 
      protein, neuronal class III beta-tubulin, and neurofilament expression were detected 
      in neurons; nestin, glial fibrillary acidic protein, microtubule-associated 
      protein 2 and chondroitin sulfate glycosaminoglycan expression were detected in 
      the NSCs. BDNF promoted significant neuronal growth (number, soma size, and 
      average neurite length), as well as NSCs proliferation and differentiation, but 
      BDNF antibody decreased neuronal growth and NSCs proliferation and 
      differentiation. RT-PCR was used to detect changes in BDNF signal pathway 
      components, showing that BDNF upregulated tropomyosin receptor kinase B, 
      phosphoinositide 3-kinase (PI3K), AKT and beta-catenin, but downregulated GSK-3beta in 
      the neurons and NSCs. BDNF antibody downregulated BDNF, tropomyosin receptor 
      kinase B, PI3K, AKT, beta-catenin and cellular-myelocytomatosis viral oncogene, but 
      upregulated GSK- 3beta, in the neurons and NSCs. CONCLUSION: Our findings suggested 
      that BDNF contributed to neuronal growth and proliferation and differentiation of 
      NSCs in vitro by stimulating PI3K/AKT/GSK3beta/beta-catenin pathways.
CI  - Copyright(c) Bentham Science Publishers; For any queries, please email at 
      epub@benthamscience.org.
FAU - Li, Xing-Tong
AU  - Li XT
AD  - Institute of Neuroscience, Kunming Medical University, Kunming, Yunnan 650500. 
      China.
FAU - Liang, Zhang
AU  - Liang Z
AD  - Institute of Neuroscience, Kunming Medical University, Kunming, Yunnan 650500. 
      China.
FAU - Wang, Tong-Tong
AU  - Wang TT
AD  - Institute of Neuroscience, Kunming Medical University, Kunming, Yunnan 650500. 
      China.
FAU - Yang, Jin-Wei
AU  - Yang JW
AD  - Institute of Neuroscience, Kunming Medical University, Kunming, Yunnan 650500. 
      China.
FAU - Ma, Wei
AU  - Ma W
AD  - Institute of Neuroscience, Kunming Medical University, Kunming, Yunnan 650500. 
      China.
FAU - Deng, Shi-Kang
AU  - Deng SK
AD  - Institute of Neuroscience, Kunming Medical University, Kunming, Yunnan 650500. 
      China.
FAU - Wang, Xian-Bin
AU  - Wang XB
AD  - Institute of Neuroscience, Kunming Medical University, Kunming, Yunnan 650500. 
      China.
FAU - Dai, Yun-Fei
AU  - Dai YF
AD  - Institute of Neuroscience, Kunming Medical University, Kunming, Yunnan 650500. 
      China.
FAU - Guo, Jian-Hui
AU  - Guo JH
AD  - Second Department of General Surgery, First People's Hospital of Yunnan Province, 
      Kunming, Yunnan. China.
FAU - Li, Li-Yan
AU  - Li LY
AD  - Institute of Neuroscience, Kunming Medical University, Kunming, Yunnan. China.
LA  - eng
PT  - Journal Article
PL  - United Arab Emirates
TA  - CNS Neurol Disord Drug Targets
JT  - CNS & neurological disorders drug targets
JID - 101269155
RN  - 0 (Brain-Derived Neurotrophic Factor)
RN  - 0 (beta Catenin)
RN  - EC 2.7.1.- (Phosphatidylinositol 3-Kinases)
RN  - EC 2.7.11.1 (Glycogen Synthase Kinase 3 beta)
RN  - EC 2.7.11.1 (Proto-Oncogene Proteins c-akt)
SB  - IM
MH  - Animals
MH  - Brain-Derived Neurotrophic Factor/antagonists & inhibitors/*physiology
MH  - Cell Division
MH  - Cells, Cultured
MH  - Glycogen Synthase Kinase 3 beta/*metabolism
MH  - Neural Stem Cells/*enzymology/*physiology
MH  - Neurogenesis/*physiology
MH  - Phosphatidylinositol 3-Kinases/*metabolism
MH  - Proto-Oncogene Proteins c-akt/*metabolism
MH  - Rats
MH  - Signal Transduction/*physiology
MH  - beta Catenin/metabolism
OTO - NOTNLM
OT  - Brain-derived neurotrophic factor
OT  - PKB
OT  - glycogen synthase kinase-3beta
OT  - neural stem cells
OT  - neurons
OT  - phosphoinositide 3-kinase
OT  - protein kinase B
OT  - beta-catenin
EDAT- 2017/05/20 06:00
MHDA- 2018/07/19 06:00
CRDT- 2017/05/20 06:00
PHST- 2017/01/19 00:00 [received]
PHST- 2017/03/07 00:00 [revised]
PHST- 2017/05/01 00:00 [accepted]
PHST- 2017/05/20 06:00 [pubmed]
PHST- 2018/07/19 06:00 [medline]
PHST- 2017/05/20 06:00 [entrez]
AID - CNSNDDT-EPUB-83560 [pii]
AID - 10.2174/1871527316666170518170422 [doi]
PST - ppublish
SO  - CNS Neurol Disord Drug Targets. 2017;16(7):828-836. doi: 
      10.2174/1871527316666170518170422.